Estrogens, menopause, and coronary artery disease

Cardiology Clinics

Volumn 14, Issue 1, 1996, Pages 105-116

  Sullivan, J M ^a   Fowlkes, L P ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ANGIOCARDIOGRAPHY; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART PROTECTION; HIGH RISK POPULATION; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MENOPAUSE; META ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0030023022     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(05)70264-2     Document Type: Article

References (57)

1. R.D. Abbott P.W.F. Wilson W.B. Kannel High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: The Framingham Study Arteriosclerosis 8 1988 207
2. M.R. Adams J.R. Kaplan S.B. Manuk Inhibition of coronary artery atherosclerosis by 17B estradiol in ovariectomized monkeys: Lack of an effect of added progesterone Arteriosclerosis 10 1990 1051 1057
3. C. Bain W.C. Willett C.H. Henenekens Use of postmenopausal hormones and risk of myocardial infarction Circulation 64 1981 42 46
4. E. Barrett-Conner D.L. Wingard M.H. Criqui Postmenopausal estrogen use and heart disease risk factors in the 1980s: Rancho Bernardo, California revisited JAMA 267 1989 2095 2100
5. C.E. Blackard R.P. Doe G.T. Mellinger Incidence of cardiovascular disease and death in patients receiving diethystilbesterol for carcinoma of the prostate Cancer 26 1970 249 256
6. T.L. Bush E. Barrett-Conner L.D. Cowan Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study Circulation 75 1987 1102 1109
7. T.L. Bush V.T. Miller Effects of pharmacologic agents used during menopause. Impact on lipids and lipoproteins D. Mishell Menopause: Physiology and Pharmacology 1986 Year Book Medical Publishers Chicago 187 208
8. G.A. Colditz K.M. Egan M.J. Stampfer Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies Am J Obstet Gynecol 168 1993 1473 1480
9. The Coronary Drug Project Research Group The coronary drug project: Initial findings leading to modifications of its research protocol JAMA 214 1970 1303 1313
10. W.D. Dupont D.L. Page Menopausal estrogen replacement therapy and breast cancer Arch Intern Med 151 1991 67 72
11. E.D. Eaker W.P. Castelli Coronary heart disease and its risk factors among women in the Framingham Study E. Eaker B. Packard N.K. Wenger Coronary Heart Disease in Women 1987 Haymarket Doyma New York 122 132
12. V.L. Ernster T.L. Bush G.R. Hugkins Benefits and risks of estrogen and/or progestin hormone use Prev Med 17 1988 201 223
13. B. Ettinger Hormone replacement therapy and coronary heart disease Obstet Gynecol Clin North Am 4 1990 741 757
14. M. Falkeborn I. Persson H.-O. Adami The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement Br J Obstet Gynaecol 99 1992 821 828
15. M. Falkeborn I. Persson A. Terens Hormone replacement therapy and the risk of stroke Arch Intern Med 153 1993 1201 1209
16. F.F. Finucane J.H. Madans T.L. Bush Decreased risk of stroke among postmenopausal hormone users: Results from a national cohort Arch Intern Med 153 1993 73 79
17. M. Fogelberg O. Vesterquist U. Dicfalusy Experimental atherosclerosis: Effects of estrogen and atherosclerosis on thromboxane and prostacyclin formation Eur J Clin Invest 20 1990 105 110
18. R.F. Furchgott J.V. Zawadzk The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine Nature 288 1980 373 376
19. D.M. Gilligan A.A. Quyyumi R.O. Cannon III Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women Circulation 89 1994 2545 2551
20. L. Goldman A.N. Tosteson Uncertainty about postmenopausal estrogen: Time for action, not debate (editorial) N Engl J Med 325 1991 800 802
21. D. Grady S.M. Rubin D.B. Petitti Hormone therapy to prevent disease and prolong life in postmenopausal women Ann Intern Med 117 1992 1016 1037
22. H.W. Gruchow A.J. Anderson J.J. Barboriak Postmenopausal use of estrogen and occlusion of coronary arteries Am Heart J 115 1988 954 963
23. J.R. Guyton G.H. Dahlen W. Patsch Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B Arteriosclerosis 5 1985 265 272
24. B.E. Henderson A. Paganini-Hill R.K. Ross Decreased mortality in users of estrogen replacement therapy Arch Intern Med 151 1991 75 78
25. B.E. Henderson A. Paganini-Hill R.K. Ross Estrogen replacement therapy and protection from acute myocardial infarction Am J Obstet Gynecol 159 1988 312 317
26. P. Henriksson B. Angelin L. Berglund Hormonal regulation of serum Lp(a) levels: Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma J Clin Invest 89 1992 1166 1171
27. D.M. Herrington G.A. Braden J.K. Williams Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy Am J Cardiol 73 1994 951 952
28. M.K. Hong P.A. Romm K. Reagan Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women Am J Cardiol 69 1992 176 178
29. L.J. Ignarro R.E. Byrns G.M. Buga Endothelium-derived relaxing factor (EDRF) released from artery and vein appears to be nitric oxide (NO) or a closely related species Fed Proc 46 1987 644
30. H. Jick B. Dinan K.J. Rothman Noncontraceptive estrogens and nonfatal myocardial infarction JAMA 239 1978 1407 1408
31. W.B. Kannel Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study Am Heart J 114 1987 413 419
32. D.J. Lerner W.B. Kannel Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population Am Heart J 113 1986 383 390
33. P.L. Ludmer A.P. Selwyn T.L. Shook Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries N Engl J Med 315 1986 1046 1051
34. K.F. McFarland M.E. Boniface C.A. Hornung Risk factors and noncontraceptive estrogen use in women with and without coronary disease Am Heart J 117 1989 1209 1214
35. A.A. Nabulsi A.R. Folsom A. White Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women N Engl J Med 328 1993 1069 1075
36. L.E. Nachtigall R.H. Nachtigall R.D. Nachtigall Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems Obstet Gynecol 54 1979 74 79
37. R.I. Pfeffer G.H. Whipple T.T. Kurosaki Coronary risk and estrogen use in postmenopausal women Am J Epidemiol 107 1978 479 487
38. R. Pick J. Stamler Rodbard S, et al: Estrogen induced regression of coronary atherosclerosis in cholesterol fed chicks Circulation 6 1952 858 861
39. S.E. Reis S.T. Gloth R.S. Blumenthal Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women Circulation 89 1994 52 60
40. G.G. Rhoads G. Dahlen K. Berg Lp(a) lipoprotein as a risk factor for myocardial infarction JAMA 256 1986 2540 2544
41. L. Rosenberg D. Slone S. Shapiro Noncontraceptive estrogens and myocardial infarction in young women JAMA 244 1980 339 342
42. R.K. Ross A. Paganini-Hill T.M. Mack Menopausal oestrogen therapy and protection from death from ischemic heart disease Lancet i 1981 858 860
43. B.B. Sherwin M.M. Gelfand A prospective one-year study of estrogen and progestin in postmenopausal women: Effects on clinical symptoms and lipoprotein lipids Obstet Gynecol 73 1989 759 766
44. M. Soma R. Fumagalli R. Paoletti Plasma Lp(a) concentration after oestrogen and progestogen in postmenopausal women (letter) Lancet 337 1991 612
45. M.J. Stampfer G.A. Colditz Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence Prev Med 20 1991 47 63
46. M.J. Stampfer G.A. Colditz W.C. Willitt Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses' Health Study N Engl J Med 325 1991 756 762
47. M.J. Stampfer W.C. Willett G.A. Colditz A prospective study of postmenopausal estrogen therapy and coronary heart disease N Engl J Med 313 1985 1044 1049
48. K.K. Steinberg S.B. Thacker J. Smith A metaanalysis of the effect of estrogen replacement therapy on the risk of breast cancer JAMA 265 1991 1985 1989
49. J.M. Sullivan R. Vander Zwaag J.P. Hughes Estrogen replacement and coronary artery disease: Effect on survival in postmenopausal women Arch Intern Med 150 1990 2557 2562
50. J.M. Sullivan R. Vander Zwaag G.F. Lemp Post-menopausal estrogen use and coronary atherosclerosis Ann Intern Med 108 1988 358 363
51. L. Weinstein Efficacy of a continuous estrogen-progestin regimen in the menopausal patient Obstet Gynecol 69 1987 929 932
52. J.K. Williams M.R. Adams H.S. Klopfenstein Estrogen modulates responses of atherosclerotic coronary arteries Circulation 81 1990 1680 1687
53. P.W. Wilson R.J. Garrison W.P. Castelli Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: The Framingham Study N Engl J Med 313 1985 1038 1043
54. P.H. Wolf J.H. Madans F.F. Finucane Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: Evidence from a national cohort Am J Obstet Gynecol 164 1991 489 494
55. The Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women JAMA 273 1995 199 208
56. J.H. Wuerst Jr T.J. Dry J.E. Edwards The degree of coronary athero-sclerosis in bilaterally oophorectomized women Circulation 7 1953 801 809
57. Y. Yui T. Aoyama H. Morishita Serum prostacyclin stabilizing factor is identical to apolipoprotein A-1 (Apo A-1): A novel function of Apo A-1 J Clin Invest 82 1988 803 807